Doxorubicin HEXAL - Doxorubicin Hydrochloride | VetSafeCare.Com

Brand

Doxorubicin HEXAL

Doxorubicin Hydrochloride — SANDOZ (A Novartis Division)
2mg / ml

Alternatives

7

Routes

IV

Presentations

1

Generic profile Browse alternatives View combinations

Presentations

IV Infusion · 2mg / ml

1 vial

৳540.27

Dose rules

No structured dose rules are linked to this brand yet.

Dose reference

Human

Administer Doxorubicin at an initial rate of 1 mg/min to minimize the risk of infusion reactions. If no infusion related reactions occur, increase rate of infusion to complete administration over 1 hour. Do not administer as bolus injection or undiluted solution. Ovarian cancer: 50 mg/m2 IV every 4 weeks AIDS-related Kaposi’s Sarcoma: 20 mg/m2 IV every 3 weeks Multiple Myeloma: 30 mg/m2 IV on day 4 following bortezomib

Clinical notes

Applications:
  • Small cell lung cancer
Indication Notes:
Doxorubicin is an anthracycline topoisomerase II inhibitor indicated for: Ovarian cancer: After failure of platinum-based chemotherapy. AIDS-related Kaposi’s Sarcoma: After failure of prior systemic chemotherapy or intolerance to such therapy. ... Read moreDoxorubicin is an anthracycline topoisomerase II inhibitor indicated for: Ovarian cancer: After failure of platinum-based chemotherapy. AIDS-related Kaposi’s Sarcoma: After failure of prior systemic chemotherapy or intolerance to such therapy. Multiple Myeloma: In combination with bortezomib in patients who have not previously received bortezomib and have received at least one prior therapy.
Avoid In:

N/A

Contraindication Notes:
Cardiac disease, neonates, pregnancy and lactation, prior irradiation to mediastinum. IM/SC admin. Severe myelosuppression due to previous treatment with antitumour agents or radiotherapy.
Doxorubicin is a cytotoxic anthracycline antibiotic. The cytotoxic action results from its binding to DNA and inhibition of nucleic acid synthesis. Doxorubicin has been shown to produce regression in a variety of disseminated malignancies.
Doxorubicin interacts with a number of other drugs e.g. antibiotics (aminoglycosides), steroids, aminophylline and propranolol.
Leucopenia, thrombocytopenia, nausea, vomiting, diarrhoea. Rarely facial flushing, rash, alopecia. Blurred vision, headache, seizures, paraesthesia, confusion, malaise, lethargy, skin pigmentation.
Acute overdosage may increase the toxic effects of mucositis, leukopenia and thrombocytopenia. Treatment includes hospitalisation of the severely myelosuppressed patient, antimicrobials, platelet transfusions and symptomatic treatment of mucositis. Use of haemopoietic growth factor (G-CSF, GM-CSF) may be considered. Cumulative dosage increases risk of cardiomyopathy and resultant congestive heart failure which may be managed with digitalis preparations, diuretics, and after load reducers such as ACE inhibitors.
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).
Elderly, children, hepatic impairment. Monitor blood counts and ECG.
Hepatic Impairment- serum-bilirubin: 12-30 mcg/ml: Half the normal dose; serum-bilirubin: >30 mcg/ml: Quarter of the usual dose.